Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Noninvasive Hemodynamic Evaluation at Rest in Heart Failure with Preserved Ejection Fraction

    Research output: Contribution to journalReviewpeer-review

  2. Causes and outcomes of hospitalizations among people living with HIV in Georgia's referral institution, 2012-2017

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sex differences in congestive markers in patients hospitalized for acute heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Self-reported vs. objectively assessed adherence to inhaled corticosteroids in asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: There is an urgent need for treatments that can shorten hospitalization and lower the risk of secondary infection and death in patients with corona disease. The ProPac-COVID trial evaluates whether combination therapy with macrolide azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy, and pre-emptive treatment of supra-infections can shorten hospitalization duration and reduce the risk of non-invasive ventilation, treatment in the intensive care unit, and death in patients with acute hospital admission and a positive test for 2019-nCoV and symptoms of COVID-19 disease.

METHODS: The ProPAC-COVID is a multi-center, randomized, placebo-controlled, double-blinded clinical trial. The primary outcome is number of days spent alive and out of hospital within 14 days from randomization. Randomization will be in blocks of unknown size, and the final allocation will be stratified for age, site of recruitment, and whether the patient has any chronic lung diseases. Data is analyzed using intention-to-treat (ITT) principles, and main analyses will also be subject to modified ITT analysis and per protocol analysis.

DISCUSSION: This paper describes the detailed statistical analysis plan for the evaluation of primary and secondary endpoints of the ProPAC-COVID study. Enrolment of patients to the ProPAC-COVID study is still ongoing. The purpose of this paper is to provide primary publication of study results to prevent selective reporting of outcomes, data-driven analysis, and to increase transparency.

TRIAL REGISTRATION: NCT04322396 . Registered on 26 March 2020.

Original languageEnglish
Article number867
Issue number1
Pages (from-to)867
Number of pages9
Publication statusPublished - 20 Oct 2020

    Research areas

  • Azithromycin, Detailed statistical analysis plan, Hydroxychloroquine, Infectious diseases, Intervention, Randomized controlled trial, Safety

ID: 61074133